Mar 26, 2025
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
Feb 04, 2021
Windtree Strengthens Its Board by Appointing Three New Directors
Feb 01, 2021
Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development
Jan 06, 2021
Windtree Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19
Sep 29, 2020
Windtree Announces FDA Acceptance of IND Application for a Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19
Sep 08, 2020
Windtree to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Jul 21, 2020
Windtree Adds to Team with Appointment of Three Industry Veterans
Jul 20, 2020
Windtree Appoints John Hamill as Chief Financial Officer
Jun 24, 2020
Windtree Announces Initial European Trial Sites Activated in AEROSURF® Bridging Study and a Collaboration for a Concomitant Independent Cerebral Physiology Study
May 20, 2020
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
May 14, 2020
Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates
Apr 29, 2020
Windtree Announces First Patient Enrolled in AEROSURF® Bridging Study for the Treatment of Respiratory Distress Syndrome
Mar 31, 2020
Windtree Enters into Agreement with Lee's Pharmaceutical for Non-Dilutive Funding of the Continued Development of AEROSURF®
Mar 24, 2020
Windtree to Pursue Clinical Study of Lung Injury Treatment in COVID-19 Patients with its KL4 Surfactant Therapy
Dec 09, 2019
Windtree Therapeutics Completes $26.4 Million Private Placement
Sep 06, 2019
Windtree Therapeutics Announces Publication of Results of Lung Deposition Study of Aerosolized Lucinactant
Aug 13, 2019
Windtree Announces FDA Fast Track Designation for Istaroxime
Jun 19, 2019
Windtree Therapeutics to Host Research & Development Day in New York City on June 25
Jun 04, 2019
Windtree and Eleison Announce Initial Results of Delivering Inhaled Lipid Cisplatin (ILC) Utilizing Windtree's Drug Delivery Technology
May 30, 2019
Istaroxime Phase 2b Study Results Presented in Late Breaker Clinical Trial Session at the ESC Heart Failure Congress